市場調查報告書

用於藥物開發和藥物發現的人工智能全球市場:按類型,指示和最終用戶分類的機會分析和行業預測:2019-2027

Artificial Intelligence For Drug Development and Discovery Market by Type, Indication,, and End User : Global Opportunity Analysis and Industry Forecast, 2019-2027

出版商 Allied Market Research 商品編碼 951397
出版日期 內容資訊 英文 210 Pages
商品交期: 2-3個工作天內
價格
用於藥物開發和藥物發現的人工智能全球市場:按類型,指示和最終用戶分類的機會分析和行業預測:2019-2027 Artificial Intelligence For Drug Development and Discovery Market by Type, Indication,, and End User : Global Opportunity Analysis and Industry Forecast, 2019-2027
出版日期: 2020年06月01日內容資訊: 英文 210 Pages
簡介

全球藥物發現和藥物開發的人工智能市場預計將從2019年的5.2億美元增長到2020年至2027年的2027年的48.15億美元。預計複合年增長率為31.6%。近年來,人工智能(AI)已用於生物學,計算機科學,心理學,數學,語言學和工程學等各個領域,在醫學領域中,藥物管理,治療計劃,藥物發現開發也是如此。預計將應用於藥物的發現和開發需要大量資金,並且臨床試驗和藥物批准的過程十分困難。製藥公司,生物技術公司和AI技術提供商之間的更大合作將推動市場增長,從而大大減少AI藥物發現過程的時間和成本,並使研究人員能夠快速準確地設計藥物諸如啟用基於雲的軟件的需求不斷增長等因素。

該報告是針對藥物開發和藥物發現的全球人工智能市場的調查,它概述了市場,按類型,指示,最終用戶,區域,競爭格局進行的分析,它提供了諸如主要公司簡介之類的信息。

內容

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
  • 主要公司的定位
  • 波特的五力分析
  • 市場動態
    • 促進增長的因素
      • 增加跨行業邊界的合作與聯盟
      • 減少藥物發現和開發過程的成本和時間
    • 生長抑製劑
      • 缺乏熟練的專業人員
      • 藥物發現領域缺乏數據集
    • 市場機會
      • 擴大對人工智能的認識
      • 發展中地區的市場不發達
    • 影響分析

第4章市場分析:按類型

  • 概述
    • 市場規模和預測
  • 藥物目標識別
  • 分子篩查
  • 從頭設計和優化藥品
  • 臨床前研究和臨床試驗

第5章按指標進行市場分析

  • 概述
    • 市場規模和預測
  • 腫瘤
  • 神經系統疾病
  • 傳染病
  • 其他

第6章市場分析:按最終用戶

  • 概述
    • 市場規模和預測
  • 製藥公司和生物技術公司
  • 研發外包機構

第7章按地區進行市場分析

  • 概述
    • 市場規模和預測
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 澳大利亞
    • 印度
    • 其他
  • 拉丁美洲/中東/非洲
    • 拉丁美洲
    • 中東/非洲

第8章公司簡介

  • ALPHABET INC.
  • ATOMWISE, INC.
  • BENEVOLENT AI
  • CLOUD PHARMACEUTICAL
  • DEEP GENOMICS
  • EXSCIENTIA.
  • IBM CORPORATION
  • INSILICO MEDICINE INC.
  • MICROSOFT CORPORATION
  • NVIDIA CORPORATION
目錄
Product Code: A04876

Title:
Artificial Intelligence For Drug Development and Discovery Market by Type (Target Identification, Molecule Screening, De Novo Drug Design & Drug Optimization, and Preclinical & Clinical Testing), Indication, (Oncology, Neurology, Infectious Disease and Others), and End User (Pharmaceutical & Biotechnology Companies, and Contract Research Organization): Global Opportunity Analysis and Industry Forecast, 2019-2027.

The artificial intelligence for drug discovery and development market was valued at $520 million in 2019 and is projected to reach $4,815 million by 2027, registering a CAGR of 31.6% from 2020 to 2027.

Artificial intelligence (AI) is science and engineering adopted to design intelligent machines, especially intelligent computer programs. AI is an intelligent system that relates various human intelligence based functions such as reasoning, learning, and problem-solving skills on different disciplines such as biology, computer science, psychology, mathematics, linguistics, and engineering. In the healthcare industry, AI is applicable in medication management, treatment plans, drug discovery& developments and others.

Drug discovery& development includes several processes and phases that demand a huge amount of funds. Furthermore, clinical trials and approval of the drug in the market might be a challenging task. Increase in number of collaborations between pharmaceutical & biotech companies and AI providers are the major driver for this market. Artificial intelligence decreases a large amount of time and cost utilized in the drug discovery and development process, which is mainly influencing the market growth. The increasing demand for cloud-based software that enables the researcher to design drugs quickly and accurately is expected to drive the market growth. Moreover, the integration of artificial intelligence (AI) and machine learning approaches within the life science R&D industry is making drug discovery and development more innovative, time-effective and cost-effective.

The artificial intelligence for drug discovery and development market is segmented on the type, indication, end user and region. By type, it is divided into target identification, molecules screening, de novo drug design &drug optimization and preclinical &clinical testing. On the basis of indication, it is classified into oncology, infectious disease, neurology, and others. By end user, it is segmented into pharmaceutical & biotechnology companies, and CROs.

Region wise, the market is analyzed across North America (US, Canada), Europe (Germany, France, UK, Rest of Europe), Asia-Pacific (Japan, China, Australia, India, Rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).North America held the major share of the artificial intelligence for drug discovery and development market in 2019 and is expected to continue its dominance during the forecast period, owing to strong economies in the U.S. and Canada; high adoption rate of AI technologies due to large number of investments to boost the drug discovery industry; and large number of cross industry collaborations and partnerships majorly fuels the market growth. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to rise in adoption of advanced AI technologies, and growth in focus of major players on increasing their presence in emerging Asian countries.

KEY MARKET SEGMENTS

By Type

  • Target Identification
  • Molecule Screening
  • De Novo Drug Design and Drug Optimization
  • Preclinical and Clinical Testing

By Indication

  • Oncology
  • Infectious Disease
  • Neurology
  • Others

By End User

  • Pharmaceutical and Biotechnology Companies.
  • Contract Research Organization (CROs).

By Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle East & Africa
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Alphabet Inc.
  • Atomwise, Inc
  • Benevolent AI
  • Cloud Pharmaceutical
  • Deep Genomics
  • Exscientia
  • Insilico Medicine Inc.
  • Microsoft Corporation
  • Nvidia Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.1. Key benefits for stakeholders
  • 1.2. Key market segments
    • 1.2.1. List of key players profiled in the report
  • 1.3. Research methodology
    • 1.3.1. Secondary research
    • 1.3.2. Primary research
    • 1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. Top player positioning, 2019
  • 3.4. Porter's five forces analysis
  • 3.5. Market dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. Growing number of cross industry collaborations and partnerships
      • 3.5.1.2. Artificial intelligence reduces cost and time utilized in the drug discovery& development process.
    • 3.5.2. Restraints
      • 3.5.2.1. Lack of skilled professionals
      • 3.5.2.2. Lack of data sets in the field of drug discovery
    • 3.5.3. Opportunity
      • 3.5.3.1. Increase in awareness related to artificial intelligence
      • 3.5.3.2. Untapped market in developing regions
    • 3.5.4. Impact Analysis

CHAPTER 4: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Target Identification
    • 4.2.1. Key market trends, growth factors, and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market analysis, by country
  • 4.3. Molecule Screening
    • 4.3.1. Key market trends, growth factors, and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market analysis, by country
  • 4.4. De Novo Drug Design and Drug Optimization
    • 4.4.1. Key market trends, growth factors, and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market analysis, by country
  • 4.5. Preclinical and clinical testing
    • 4.5.1. Key market trends, growth factors, and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market analysis, by country

CHAPTER 5: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oncology
    • 5.2.1. Market size and forecast, by region
    • 5.2.2. Market analysis, by country
  • 5.3. Neurology
    • 5.3.1. Market size and forecast, by region
    • 5.3.2. Market analysis, by country
  • 5.4. Infectious Disease
    • 5.4.1. Market size and forecast, by region
    • 5.4.2. Market analysis, by country
  • 5.5. Others
    • 5.5.1. Market size and forecast, by region
    • 5.5.2. Market analysis, by country

CHAPTER 6: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Pharmaceutical and biotechnology companies
    • 6.2.1. Market size and forecast, by region
    • 6.2.2. Market analysis, by country
  • 6.3. Contract Research Organization
    • 6.3.1. Market size and forecast, by region
    • 6.3.2. Market analysis, by country

CHAPTER 7: GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors, and opportunities
    • 7.2.2. North America artificial intelligence for drug discovery and development , by country
      • 7.2.2.1. U.S.
      • 7.2.2.1.1. U.S. artificial intelligence for drug discovery and development market, by type
      • 7.2.2.1.2. U.S artificial intelligence for drug discovery and development market, by indication
      • 7.2.2.1.3. U.S. artificial intelligence for drug discovery and development market, by end user
      • 7.2.2.2. Canada
      • 7.2.2.2.1. Canada artificial intelligence for drug discovery and development market, by type
      • 7.2.2.2.2. Canada artificial intelligence for drug discovery and development market, by indication
      • 7.2.2.2.3. Canada artificial intelligence for drug discovery and development market, by end user
    • 7.2.3. North America artificial intelligence for drug discovery and development market, by type
    • 7.2.4. North America artificial intelligence for drug discovery and development , by indication
    • 7.2.5. North America artificial intelligence for drug discovery and development , by end user
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors, and opportunities
    • 7.3.2. Europe artificial intelligence for drug discovery and development , by country
      • 7.3.2.1. UK artificial intelligence for drug discovery and development market, by type
      • 7.3.2.1.1. UK artificial intelligence for drug discovery and development market, by type
      • 7.3.2.1.2. UK artificial intelligence for drug discovery and development market, by indication
      • 7.3.2.1.3. UK artificial intelligence for drug discovery and development market, by end user
      • 7.3.2.2. Germany
      • 7.3.2.2.1. Germany artificial intelligence for drug discovery and development market, by type
      • 7.3.2.2.2. Germany artificial intelligence for drug discovery and development market, by indication
      • 7.3.2.2.3. Germany artificial intelligence for drug discovery and development market, by end user
      • 7.3.2.3. France
      • 7.3.2.3.1. France artificial intelligence for drug discovery and development market, by type
      • 7.3.2.3.2. France artificial intelligence for drug discovery and development market, by indication
      • 7.3.2.3.3. France artificial intelligence for drug discovery and development market, by end user
      • 7.3.2.4. Rest of Europe
      • 7.3.2.4.1. Rest of Europe artificial intelligence for drug discovery and development market, by type
      • 7.3.2.4.2. Rest of Europe artificial intelligence for drug discovery and development market, by indication
      • 7.3.2.4.3. Rest of Europe artificial intelligence for drug discovery and development market, by end user
    • 7.3.3. Europe artificial intelligence for drug discovery and development , by type
    • 7.3.4. Europe artificial intelligence for drug discovery and development , by indication
    • 7.3.5. Europe artificial intelligence for drug discovery and development , by end user
  • 7.4. Asia-pacific
    • 7.4.1. Key market trends, growth factors, and opportunities
    • 7.4.2. Asia-Pacific artificial intelligence for drug discovery and development , by country
      • 7.4.2.1. Japan
      • 7.4.2.1.1. Japan artificial intelligence for drug discovery and development market, by type
      • 7.4.2.1.2. Japan artificial intelligence for drug discovery and development market, by indication
      • 7.4.2.1.3. Japan artificial intelligence for drug discovery and development market, by end user
      • 7.4.2.2. China
      • 7.4.2.2.1. China artificial intelligence for drug discovery and development market, by type
      • 7.4.2.2.2. China artificial intelligence for drug discovery and development market, by indication
      • 7.4.2.2.3. China artificial intelligence for drug discovery and development market, by end user
      • 7.4.2.3. Australia
      • 7.4.2.3.1. .Australia artificial intelligence for drug discovery and development market, by type
      • 7.4.2.3.2. Australia artificial intelligence for drug discovery and development market, by indication
      • 7.4.2.3.3. Australia artificial intelligence for drug discovery and development market, by end user
      • 7.4.2.4. India
      • 7.4.2.4.1. India artificial intelligence for drug discovery and development market, by type
      • 7.4.2.4.2. India artificial intelligence for drug discovery and development market, by indication
      • 7.4.2.4.3. India artificial intelligence for drug discovery and development market, by end user
      • 7.4.2.5. Rest of Asia-Pacific
      • 7.4.2.5.1. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by type
      • 7.4.2.5.2. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by indication
      • 7.4.2.5.3. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by end user
    • 7.4.3. Asia-Pacific artificial intelligence for drug discovery and development , by type
    • 7.4.4. Asia-Pacific artificial intelligence for drug discovery and development , by indication
    • 7.4.5. Asia-Pacific artificial intelligence for drug discovery and development , by end user
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors, and opportunities
    • 7.5.2. LAMEA artificial intelligence for drug discovery and development , by country
      • 7.5.2.1. Latin America
      • 7.5.2.1.1. Latin America artificial intelligence for drug discovery and development market, by type
      • 7.5.2.1.2. Latin America artificial intelligence for drug discovery and development market, by indication
      • 7.5.2.1.3. Latin America artificial intelligence for drug discovery and development market, by end user
      • 7.5.2.2. Middle east and Africa
      • 7.5.2.2.1. Middle east and Africa artificial intelligence for drug discovery and development market, by type
      • 7.5.2.2.2. Middle east and Africa artificial intelligence for drug discovery and development market, by indication
      • 7.5.2.2.3. Middle east and Africa artificial intelligence for drug discovery and development market, by end user

CHAPTER 8: COMPANY PROFILES

  • 8.1. ALPHABET INC.
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Product portfolio
    • 8.1.5. Business performance
  • 8.2. ATOMWISE, INC.
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segment
    • 8.2.4. Product portfolio
    • 8.2.5. Key strategic moves and developments
  • 8.3. BENEVOLENT AI
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segment
    • 8.3.4. Product portfolio
    • 8.3.5. Key strategic moves and developments
  • 8.4. CLOUD PHARMACEUTICAL
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segment
    • 8.4.4. Product portfolio
    • 8.4.5. Key strategic moves and developments
  • 8.5. DEEP GENOMICS
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segment
    • 8.5.4. Product portfolio
  • 8.6. EXSCIENTIA.
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segment
    • 8.6.4. Product portfolio
    • 8.6.5. Key strategic moves and developments
  • 8.7. IBM CORPORATION
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Product portfolio
    • 8.7.5. Business performance
    • 8.7.6. Key strategic moves and developments
  • 8.8. INSILICO MEDICINE INC.
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segment
    • 8.8.4. Product portfolio
    • 8.8.5. Key strategic moves and developments
  • 8.9. MICROSOFT CORPORATION
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Product portfolio
    • 8.9.5. Business performance
    • 8.9.6. Key strategic moves and developments
  • 8.10. NVIDIA CORPORATION
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Product portfolio
    • 8.10.5. Business performance

LIST OF TABLES

  • TABLE 01. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 02. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FORTARGET IDENTIFICATION, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FOR MOLECULE SCREENING, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FORDE NOVO DRUG DESIGN AND DRUG OPTIMIZATION, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FOR DE NOVO DRUG DESIGN AND DRUG OPTIMIZATION, BY REGION, 2019-2027 ($MILLION)
  • TABLE 06. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, BY INDICATION, 2019-2027($MILLION)
  • TABLE 07. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY ONCOLOGY, 2019-2027 ($MILLION)
  • TABLE 08. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY NEUROLOGY, 2019-2027 ($MILLION)
  • TABLE 09. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY INFECTIOUS DISEASE, 2019-2027 ($MILLION)
  • TABLE 10. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY OTHERS, 2019-2027 ($MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2019-2027 ($MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY CONTRACT RESEARCH ORGANIZATION, 2019-2027 ($MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 15. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 16. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 17. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 18. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT, BY END USER, 2019-2027 ($MILLION)
  • TABLE 19. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 20. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 21. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 22. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 23. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 24. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 25. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 26. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 27. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 28. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 29. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 30. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 31. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 32. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 33. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 34. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 35. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 36. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 37. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 38. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 39. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 40. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 41. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 42. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 43. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 44. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 45. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 46. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 47. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 48. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 49. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 50. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 51. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 52. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 53. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 54. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 55. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 56. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 57. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 58. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 59. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 60. LAMEA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 61. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 62. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 63. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 64. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
  • TABLE 65. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 66. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
  • TABLE 67. ALPHABET INC.: COMPANY SNAPSHOT
  • TABLE 68. ALPHABET INC.: OPERATING SEGMENTS
  • TABLE 69. ALPHABET INC.: PRODUCT PORTFOLIO
  • TABLE 70. ATOMWISE: COMPANY SNAPSHOT
  • TABLE 71. ATOMWISE: PRODUCT PORTFOLIO
  • TABLE 72. BENEVOLENT: COMPANY SNAPSHOT
  • TABLE 73. BENEVOLENT: PRODUCT PORTFOLIO
  • TABLE 74. CLOUD: COMPANY SNAPSHOT
  • TABLE 75. CLOUD: PRODUCT PORTFOLIO
  • TABLE 76. DEEP: COMPANY SNAPSHOT
  • TABLE 77. DEEP: PRODUCT PORTFOLIO
  • TABLE 78. EXSCIENTIA: COMPANY SNAPSHOT
  • TABLE 79. EXSCIENTIA: PRODUCT PORTFOLIO
  • TABLE 80. IBM CORPORATION: COMPANY SNAPSHOT
  • TABLE 81. IBM: OPERATING SEGMENTS
  • TABLE 82. IBM: PRODUCT PORTFOLIO
  • TABLE 83. INSILICO: COMPANY SNAPSHOT
  • TABLE 84. INSILICO: PRODUCT PORTFOLIO
  • TABLE 85. MICROSOFT CORPORATION: COMPANY SNAPSHOT
  • TABLE 86. MICROSOFT CORPORATION: OPERATING SEGMENTS
  • TABLE 87. MICROSOFT: PRODUCT PORTFOLIO
  • TABLE 88. NVIDIA: COMPANY SNAPSHOT
  • TABLE 89. NVIDIA: OPERATING SEGMENTS
  • TABLE 90. NVIDIA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2017-2020*
  • FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2020* (%)
  • FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2017-2020*
  • FIGURE 06. TOP PLAYER POSITIONING, 2019
  • FIGURE 07. MODERATE BARGANING POWER OF SUPPLIER
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. LOW THREAT OF NEW ENTRANT
  • FIGURE 10. LOW THREAT OF SUBSTITUTION
  • FIGURE 11. HIGH COMPETITIVE RIVALRY
  • FIGURE 12. IMPACT ANALYSIS
  • FIGURE 13. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, FOR TARGET IDENTIFICATIONBY COUNTRY, 2019 & 2027(%)
  • FIGURE 14. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, FOR MOLECULE SCREENINGBY COUNTRY, 2019 &2027 (%)
  • FIGURE 15. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, FOR DE NOVO DRUG DESIGN AND DRUG OPTIMIZATION BY COUNTRY, 2019 &2027(%)
  • FIGURE 16. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, FOR DE NOVO DRUG DESIGN AND DRUG OPTIMIZATION BY COUNTRY, 2019 &2027(%)
  • FIGURE 17. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, FOR ONCOLOGYBY COUNTRY, 2019 & 2027 (%)
  • FIGURE 18. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, FOR NEUROLOGY BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 19. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, FOR INFECTIOUS DISEASEBY COUNTRY, 2019 & 2027 (%)
  • FIGURE 20. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, FOR OTHERSBY COUNTRY, 2019 & 2027 (%)
  • FIGURE 21. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIESBY COUNTRY, 2019 & 2027 (%)
  • FIGURE 22. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, FOR CONTRACT RESEARCH ORGANIZATION BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 23. ALPHABET INC.: REVENUE, 20187-2019 ($MILLION)
  • FIGURE 24. ALPHABET INC.: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 25. ALPHABET INC.: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 26. IBM: REVENUE, 2017-2019 ($MILLION)
  • FIGURE 27. IBM: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 28. IBM: REVENUE SHARE BY REGION 2019 (%)
  • FIGURE 29. MICROSOFT CORPORATION: REVENUE, 2017-2019 ($MILLION)
  • FIGURE 30. MICROSOFT CORPORATION: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 31. MICROSOFT CORPORATION: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 32. NVIDIA: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 33. NVIDIA: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 34. NVIDIA: REVENUE SHARE BY REGION, 2020 (%)